Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619405 · ClinicalTrials.gov registry record · NA
AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
A NA study of Age-related Macular Degeneration, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06619405: Recruiting NA study of Age-related Macular Degeneration, sponsored by Duke University.
NCT06619405 is a NA study of Age-related Macular Degeneration that is actively recruiting participants, run by Duke University. The registered enrollment target is 100 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06619405, a NA study of Age-related Macular Degeneration, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal is to conduct a cross-sectional, single timepoint study on older adults with early and intermediate AMD, and with subretinal drusenoid deposits (SDD), and those in normal health, establishing an association between dark adaptation and reading performance under dim illumination, both which depend on rod photoreceptors.
Primary Outcome
Total EZ attenuation is defined as EZ-RPE (retinal pigment epithelium) thickness = 0 μm.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Streetlab VR
Study Locations (1)
North Carolina
- Duke Eye Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06619405 shows while recruiting
NCT06619405 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Streetlab VR is the first listed.
NCT06619405 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06619405 about?
NCT06619405 is a clinical study titled "AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance". The goal is to conduct a cross-sectional, single timepoint study on older adults with early and intermediate AMD, and with subretinal drusenoid deposits (SDD), and those in normal health, establishing an association between dark adaptation and reading performance under dim illumination, both which d...
What is the current status of trial NCT06619405?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-08-15. Estimated completion is 2027-12-31.
What conditions does trial NCT06619405 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT06619405?
The interventions under investigation include: Streetlab VR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06619405?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06619405 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06619405's enrollment target sits among peer trials
100 31st of 74 higher than 42 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
RECRUITING · NA
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI